H&R GmbH & Co (2HRA) Fair Value & Analysis
Basic Materials · DE · Market cap €223M
Fair value as of: Jul 13, 2026
From 15 valuation models · updated 28 days ago
Fair value updated Jul 13, 2026, revised from €2.85 to €5.70 (+100.0%) since Jun 25, 2026. Share price +0.7% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- The models converge in a tight band (€5.70 to €5.98), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 13, 2026.
How to read this chart
60‑month range €3.20 – €9.66 · fair‑value band €5.70 – €5.98 · the €6.04 price screens above the €5.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 13, 2026.
Analysis
H&R GmbH & Co (2HRA) currently trades at €6.04, while our model-based Fair Value estimate is €5.70, implying the stock looks roughly 5.6% fairly valued today. The Quality Score stands at 46/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, H&R GmbH & Co generated revenue of €1.2B at a net margin of -3.1%. Revenue declined 13.2% year over year. It earns a return on equity of -7.6%. Net debt stands at €112M. Fundamentals as of Jul 13, 2026
Our scenario range runs from €5.70 (bear case) to €5.98 (bull case); at €6.04, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 54% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -58% fair-value upside, at -6%, 2HRA screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: DCF Models (€10.92) versus Dividend Discount (€0.8700). Highest evidence: Growth DCF (80).
Notify me when 2HRA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 45 · Market factors (momentum, volatility) 74
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
H&R GmbH & Co. KGaA engages in the production and sale of chemical-pharmaceutical raw materials and injection molded precision plastic parts worldwide. It operates through three segments: ChemPharm Refining, ChemPharm Sales, and Plastics.
Full company description
H&R GmbH & Co. KGaA engages in the production and sale of chemical-pharmaceutical raw materials and injection molded precision plastic parts worldwide. It operates through three segments: ChemPharm Refining, ChemPharm Sales, and Plastics. The ChemPharm Refining segment offers paraffins, white oils, plasticizers, base oils, lubricants, and other crude-oil based specialty products, as well as bitumen, feedstocks, and bunker fuel. The ChemPharm Sales segment provides paraffins, plasticizers, wax emulsions, and other crude-oil based specialty products. The Plastics segment develops, manufactures, and sells high-precision plastic parts. The company also provides petroleum jellies, cosmetic and pharmaceutical specialties, process oils, and cable fillers, as well as polymers and APP based products for the construction industry. The company was formerly known as H&R AG and changed its name to H&R GmbH & Co. KGaA in August 2016. H&R GmbH & Co. KGaA was founded in 1919 and is headquartered in Salzbergen, Germany.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
H&R GmbH & Co reported revenue of €1.2B in FY2025 versus €1.2B in FY2021, a compound +1.1%/yr. Reported net income was −€38.8M in FY2025.
of which total revenue +4.3 pp · buybacks/dilution −0.2 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 2HRA: get an alert when its fair value changes →
Peer Group
Specialty Chemicals · 673 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $489.98 | $222.03 | -55% |
| Nan Ya Plastics Corporation 1303 | 181.50 TWD | 255.83 TWD | +41% |
| Wanhua Chemical Group 600309 | ¥70.04 | ¥68.03 | -3% |
| Novozymes A/S NSISB | kr 428.20 | kr 179.66 | -58% |
| Asian Paints Limited ASIANPAINT | ₹2,689 | ₹668.81 | -75% |
| Solar Industries India Limited SOLARINDS | ₹18,236 | ₹2,793 | -85% |
| Pidilite Industries Limited PIDILITIND | ₹1,560 | ₹351.84 | -77% |
| PT Chandra Asri Pacific Tbk TPIA | 1,805 IDR | 2,888 IDR | +60% |
| Linde India Limited LINDEINDIA | ₹7,115 | ₹757.93 | -89% |
| Berger Paints India Limited BERGEPAINT | ₹493.70 | ₹164.29 | -67% |
Compare H&R GmbH & Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is H&R GmbH & Co (2HRA) overvalued or undervalued?
What is the fair value of 2HRA?
What is the quality score of 2HRA?
What is the revenue of H&R GmbH & Co (2HRA)?
What is the net profit margin of 2HRA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track H&R GmbH & Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.